Compare NKSH & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKSH | ALLO |
|---|---|---|
| Founded | 1891 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.3M | 252.9M |
| IPO Year | 1995 | 2018 |
| Metric | NKSH | ALLO |
|---|---|---|
| Price | $38.41 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.27 |
| AVG Volume (30 Days) | 12.4K | ★ 6.4M |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $7,474,000.00 | $22,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.62 | ★ N/A |
| Revenue Growth | ★ 5.68 | N/A |
| 52 Week Low | $23.75 | $0.86 |
| 52 Week High | $40.00 | $2.32 |
| Indicator | NKSH | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 68.65 | 60.69 |
| Support Level | $37.54 | $1.56 |
| Resistance Level | $38.72 | $2.30 |
| Average True Range (ATR) | 0.83 | 0.17 |
| MACD | -0.13 | 0.04 |
| Stochastic Oscillator | 53.67 | 64.86 |
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.